We are 3-(4-Methylbenzylidene)camphor CAS:38102-62-4 manufacturer and supplier in China, Pls send inquiry of to firstname.lastname@example.org of visit www.nbinno.com our official website should you have any interests
Related News: It is foreseeable that in the future, the capacity and output of bulk APIs in China will decrease, the supply-demand relationship will be balanced, and prices and profits will gradually return to a more reasonable range. The era of low prices in the past will be gone forever. Individual APIs Varieties may even lose their price competitive advantage and move abroad.2,5-Dichloro-3-nitropyridine China’s basic chemical industry is developed, and the intermediate industry has also entered a mature stage. It is basically able to independently support the production needs of various domestic drug substances, which also brings cost advantages to Chinese drug substance companies. On the other hand, if there is insufficient supply of upstream products or price fluctuations, the sales of API products will also fluctuate in volume and price.Ethyl (E)-7-[4-(4'-fluorophenyl)-2-(cyclopropyl)-3-quinolinyl]-5-hydroxy-3-oxo-6-heptenoate China has granted conditional approval to its first self-developed treatment for Alzheimer’s disease, a move that may point to revived opportunities in a therapeutic area where drugmakers have burned billions of dollars without yielding a validated new drug.2-etil-3-metilpirazina CAS:15707-23-0 A key publication in a preclinical model demonstrated rigosertib’s ability to block cellular signaling by targeting RAS effector pathways (Divakar, S.K., et al., 2016: “A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.” Cell 165, 643).It does not require a production license for the drug substance, and can be produced in an ordinary chemical plant. As long as it reaches a certain level, it can be used for the synthesis of the drug substance.